Immunotherapy provides long-term survival benefit: Further evidence in lung cancer – Medical Xpress
Medical Xpress |
Immunotherapy provides long-term survival benefit: Further evidence in lung cancer
Medical Xpress Researchers presented the three-year survival results of the randomised phase 2 POPLAR trial in second line, which is the longest follow-up reported to date with anti-programmed death ligand 1 (PD-L1) immunotherapy in patients with previously treated … |
